Clinical TrialJul 15, 2026, 07:01 AM
Tempest Therapeutics Advances TPST-4003 into Clinical Trial
AI Summary
Tempest Therapeutics announced details of its next-generation in vivo CAR-T platform, with its lead candidate TPST-4003 set to enter an investigator-initiated clinical trial. The trial will focus on nervous system autoimmune diseases like myasthenia gravis and multiple sclerosis, with first patient dosing expected in Q4 2026 and initial data in H1 2027. TPST-4003 utilizes a CD7-targeted mRNA/LNP delivery and a dual-targeting CD19/BCMA CAR construct, building on the success of TPST-2003 which achieved a 100% complete response rate.
Key Highlights
- Tempest Therapeutics to advance lead candidate TPST-4003 into an investigator-initiated trial.
- Trial will enroll approximately 10 patients with nervous system autoimmune diseases (MG, MS).
- First patient dosing for TPST-4003 anticipated in Q4 2026.
- Initial clinical data from TPST-4003 trial expected in H1 2027.
- TPST-4003 combines CD7-targeted mRNA/LNP delivery with dual-targeting CD19/BCMA CAR construct.
- TPST-2003, using a similar CAR construct, showed 100% complete response in interim Phase 1/2a data.
Price Impact
More from TPST